OpenAI acquires Orchestra Bio to advance AI drug development

Ollie Chang

, Taipei

Oct 22, 2026, 12:03 0

Credit: DIGITIMES

OpenAI has acquired biotech startup Orchestra Bio and will integrate its team and technology into its life sciences research platform, Rosalind, expanding AI applications in drug development in an effort to accelerate the arrival of new therapies.

The article requires paid subscription. Subscribe Now

Email address

Password

Keep me signed in

Keep me signed in

Some subscribers prefer to save their log-in information so they do not have to enter their User ID and Password each time they visit the site. To activate this function, check the 'Keep me signed in' box in the log-in section. This will save the password on the computer you're using to access the site.

Note: If you choose to use the log-out feature, you will lose your saved information. This means you will be required to log-in the next time you visit our site.

Enterprise first-time login?

Forgot your password?

Create your free account

Select premium stories & daily editor picks.
Leverage AI summaries for instant insights.
Receive tech briefings & newsletters.
Track financials & stock data of Taiwan tech.

No credit card required

BIZ FOCUS

Oct 22, 08:00

HOYA BIT Explores AI Data Analysis Solutions for Smarter Trading

MOST-READ
7 DAYS NEWS

Full list